Most antibody programmes do not fail at hit discovery. They stall later, when a lead selected for binding alone reveals developability liabilities that only surface at CMC. Nearly one in three antibodies that reached Phase 2 still carried multiple developability red flags (Jain et al., PNAS 2017).

Our platforms and technologies are built to remove that risk at the source. 

Each one selects, sees, predicts, or generates with developability in view from day one, so what you select is what you develop. Discovery, engineering, characterisation, and structural biology run as one integrated workflow, under one scientific leadership. Sequence-level data flows from hit identification through to CMC without re-characterisation: one team, one dataset, one timeline.